Business
ASX 200 on watch after study shows Moderna’s COVID-19 vaccine is 94.5% effective // Motley Fool Australia
The S&P/ASX 200 Index (ASX: XJO) could be given a boost today from news that there is now a second potentially effective COVID-19 vaccine.
Overnight, biotechnology company Moderna released an update on its Phase 3 study of mRNA-1273.
What did Moderna announce?
According to the release, the National Institutes of Health-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.
This study enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).
The primary endpoint of the…
-
Business23 hours agoprofit up 7%, guidance strong
-
Noosa News21 hours agoItalian Film Festival, Brisbane: All the Details
-
Noosa News16 hours agoKatter and pregnant wife crash-land plane in outback Qld
-
Noosa News16 hours agoFollowing Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’